Pembrolizumab in Patients With Non-Small Cell Lung Cancer and a Performance Status 2

Sponsor
University of Birmingham
Study ID
NCT02733159
Phase
PHASE2
Status
Completed

Conditions

  • Carcinoma, Non-Small-Cell Lung

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • pembrolizumab — DRUG
    anti PD-1

Study Details

This study is to determine that pembrolizumab is safe and tolerable at the selected dose for the treatment of Non-Small Cell Lung Cancer (NSCLC) in patients with a performance status of 2. All patients will receive pembrolizumab.

Key Dates

Start date
Jan 4, 2017
Status verified
Jan 2025
Primary completion
Feb 7, 2023
Completion
Feb 5, 2024

Study Design

Enrollment
62 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Pembrolizumab
    Pembrolizumab: 200 mg Q3W, intravenous administration for a maximum of 2 years, or until progression or unacceptable toxicity.

Primary Outcome Measure

Toxicity Rate [ Time Frame: Date of patient registration until 6 months after the administration of the last treatment (a maximum of 2 years treatment and 6 months followup after end of treatment) ]

Related coverage on Hipa.ai

Related Studies